Trial Profile

An Investigator Initiated, Phase II Study of Linifanib in Patients With Advanced, Refractory Colorectal Cancer Expressing Mutated kRas.

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Linifanib (Primary)
Indications Colorectal cancer
Focus Therapeutic Use

Most Recent Events

28 Mar 2017 Primary endpoint (Overall Response Rate (Complete Response + Partial Response) With a Target of at Least 15%) has not been met, according to the results published in the Investigational New Drugs
28 Mar 2017 Results published in the Investigational New Drugs
06 Mar 2013 Planned End Date changed from 1 Mar 2017 to 1 Mar 2018 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com